Veterans Affairs seamless phase II/III randomized trial of STAndard systemic theRapy with or without PET-directed local therapy for OligoRecurrenT prostate cancer (VA STARPORT)
退伍军人事务部无缝 II/III 期 STAndard 全身治疗随机试验,有或没有 PET 定向局部治疗,用于治疗寡复发性前列腺癌 (VA STARPORT)
基本信息
- 批准号:10357571
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:AdoptionAndrogen ReceptorAreaBiological MarkersBody partCancer ControlCancer EtiologyCessation of lifeCharacteristicsClinicalClinical Trials DesignCollaborationsCombined Modality TherapyDNA sequencingDataDevelopmentDiseaseDisease OutcomeEffectivenessEligibility DeterminationEnrollmentFailureGoalsGrowthHealthcare SystemsHormonalImageInterdisciplinary StudyLeadLocal TherapyMalignant NeoplasmsMalignant neoplasm of prostateMeasuresMetastatic Prostate CancerMetastatic/RecurrentMethodologyMolecularMutationNeoplasm MetastasisOperative Surgical ProceduresOutcomePatientsPatternPhasePositron-Emission TomographyPrimary NeoplasmProgression-Free SurvivalsProstateProstate Cancer therapyQuality of lifeRNARadiationRadiation therapyRecurrenceSiteSystemic TherapyTestingTherapeutic AgentsUnited States Department of Veterans AffairsVeteransVitelliform macular dystrophyWidespread Diseasebasecancer diagnosischemotherapycooperative studycost effectivenesscurative treatmentsdisorder controleconomic evaluationhealth economicshealth related quality of lifehormone therapyimprovedimproved outcomemenmolecular subtypesmortalitynovelnovel therapeuticsoncology programpalliativepatient subsetsphase III trialprecision oncologypreventprimary endpointprogramsrandomized trialresponsestandard of caretargeted agenttranscriptomicstrial comparingtumortumor progression
项目摘要
Prostate Cancer is the most commonly diagnosed cancer among Veterans, comprising 30% of
new cancer diagnoses in the VA. Eighty-five percent of men present with localized prostate can-
cer, which is typically treated with active surveillance or curative local therapy using surgery or
radiation therapy. Unfortunately, twenty percent of Veterans undergoing curative local therapy
will develop metastatic recurrence. These men typically receive palliative systemic hormonal
therapy to control their disease. Despite this, over half of men will have cancer progression
within 1-2 years and half will die within 5 years.
Two diverging paradigms have been studied in recent years to improve the survival of men with
recurrent metastatic prostate cancer. First, a subset of patients has oligorecurrent disease, de-
fined as 1-5 sites of metastases. These patients are hypothesized to have an intermediate clini-
cal state in which ablative local therapy with surgery or radiation to all metastatic sites of dis-
ease (metastasis-directed therapy; MDT) can lead to durable disease control and potentially
cure in select patients. Recent Phase II randomized trials have demonstrated improved long-
term progression-free survival with MDT in the absence of systemic therapy.
Yet, 75% of patients receiving MDT for oligorecurrent cancer develop progression in new areas,
arguing that systemic therapy is needed to treat occult metastases. This is supported by data
demonstrating that earlier palliative hormonal therapy is associated with improved survival. In
fact, the second approach that has been studied in recent years, is whether escalating hormonal
therapy by adding novel androgen receptor axis targeted agents or chemotherapy improves out-
comes in men with metastatic prostate cancer. Multiple phase III randomized trials demonstrate
that escalating hormonal therapy with these novel therapeutic agents improves progression-free
survival and overall survival dramatically. Therefore, these agents have been integrated as an
option into today’s standard systemic therapy (SST) for metastatic recurrence.
Given the promise of MDT to induce long-term cancer control and the effectiveness of SST to
prevent further cancer progression, there is an urgent need to determine whether adding MDT
to SST improves disease outcomes further. The primary goal of our study is to determine if add-
ing MDT improves disease control compared to SST alone in Veterans with oligorecurrent pros-
tate cancer. We will conduct a multi-institutional phase II randomized trial comparing SST with
or without MDT. Other goals of the study are to determine any differences in patterns of cancer
progression, survival, quality of life, and the cost-effectiveness of each approach. We also will
determine how RNA transcriptomic analysis and DNA sequencing of the primary tumor from the
original prostate cancer diagnosis can help determine which Veterans benefit the most from
MDT. We will also utilize the VA National Precision Oncology Program to sequence metastases.
The trial was developed and will be conducted in collaboration with the VA Cooperative Studies
Program (CSP), and represents the multidisciplinary collaboration of prostate cancer experts,
MDT experts, clinical trial design experts, and Veterans.
If MDT improves FFS, our study will serve as the basis to develop a definitive phase III random-
ized trial that will be powered to determine if MDT improves overall survival—establishing the
new standard of care.
前列腺癌是退伍军人中最常见的癌症,占30%。
退伍军人事务部新的癌症诊断85%的局限性前列腺患者
cer,通常采用积极监测或手术或局部治疗进行治疗,
放射治疗不幸的是,百分之二十的退伍军人接受治疗性局部治疗,
会出现转移性复发这些人通常接受姑息性全身激素
治疗以控制疾病。尽管如此,超过一半的男性将有癌症进展
在1-2年内死亡,一半在5年内死亡。
近年来研究了两种不同的范式,以提高男性的生存率,
复发转移性前列腺癌首先,一部分患者患有复发性疾病,
以1-5个转移灶为标准。这些患者被假设有一个中间临床-
在这种状态下,对所有转移部位进行手术或放射的消融性局部治疗,
转移导向治疗(MDT)可以导致持久的疾病控制,
在特定患者中治愈。最近的II期随机试验表明,
无全身治疗情况下MDT的长期无进展生存期。
然而,75%的接受MDT治疗的少复发性癌症患者在新的领域出现进展,
认为需要全身治疗来治疗隐匿性转移。这是有数据支持的
这表明早期姑息性激素治疗与生存率的提高有关。在
事实上,近年来研究的第二种方法是,
通过添加新的雄激素受体轴靶向药物或化疗的治疗改善了
是转移性前列腺癌患者多项III期随机试验证明
使用这些新型治疗剂的激素治疗可以改善无进展
生存率和总体生存率都有很大的提高。因此,这些代理已被整合为
选择进入今天的标准全身治疗(SST)转移复发。
考虑到MDT诱导长期癌症控制的前景和SST的有效性,
预防癌症进一步进展,迫切需要确定是否增加MDT
SST可进一步改善疾病结局。我们研究的主要目的是确定是否添加-
与SST单独治疗相比,MDT可改善患有少复发性前列腺癌的退伍军人的疾病控制
泰特癌症。我们将进行一项多机构II期随机试验,比较SST与
或者没有MDT。这项研究的其他目标是确定癌症模式的任何差异
进展,生存,生活质量,以及每种方法的成本效益。我们也将
确定RNA转录组学分析和DNA测序如何从原发性肿瘤
最初的前列腺癌诊断可以帮助确定哪些退伍军人受益最多
数据终端我们还将利用VA国家精确肿瘤学计划对转移进行测序。
该试验是与VA合作研究合作开发的,
计划(CSP),并代表了前列腺癌专家的多学科合作,
MDT专家、临床试验设计专家和退伍军人。
如果MDT能改善FFS,我们的研究将作为制定明确的III期随机-
有把握度确定MDT是否改善总体生存率的标准化试验-确定
新的护理标准。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Abhishek Ashok Solanki其他文献
Abhishek Ashok Solanki的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Abhishek Ashok Solanki', 18)}}的其他基金
Veterans Affairs seamless phase II/III randomized trial of STAndard systemic theRapy with or without PET-directed local therapy for OligoRecurrenT prostate cancer (VA STARPORT)
退伍军人事务部无缝 II/III 期 STAndard 全身治疗随机试验,有或没有 PET 定向局部治疗,用于治疗寡复发性前列腺癌 (VA STARPORT)
- 批准号:
10578677 - 财政年份:2021
- 资助金额:
-- - 项目类别:
相似海外基金
Androgen receptor: A master regulator of lipid metabolism
雄激素受体:脂质代谢的主要调节因子
- 批准号:
DP230103210 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Discovery Projects
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation
通过蛋白质精氨酸甲基化调节前列腺癌中的雄激素受体信号传导
- 批准号:
10584689 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Structural and functional analysis of a novel class of androgen receptor antagonists
一类新型雄激素受体拮抗剂的结构和功能分析
- 批准号:
10650956 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Role of the Androgen Receptor in Insulin Secretion in the Male
雄激素受体在男性胰岛素分泌中的作用
- 批准号:
10488954 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Targeting tumor cell macrophage lipid interactions to overcome resistance to androgen receptor targeted therapy
靶向肿瘤细胞巨噬细胞脂质相互作用以克服对雄激素受体靶向治疗的耐药性
- 批准号:
10651105 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease
ONCT-505(一种雄激素受体拮抗剂和降解剂)的临床前开发,作为肯尼迪病的新潜在治疗方法
- 批准号:
10603636 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Proliferating cell nuclear antigen in regulation of androgen receptor signalings in castration-resistant prostate cancer cells
增殖细胞核抗原对去势抵抗性前列腺癌细胞雄激素受体信号传导的调节
- 批准号:
10544062 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Effects of androgen receptor (AR) signaling on CD4+ T cell metabolism during airway inflammation
气道炎症期间雄激素受体 (AR) 信号对 CD4 T 细胞代谢的影响
- 批准号:
10534943 - 财政年份:2022
- 资助金额:
-- - 项目类别:
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE
标题:使用雄激素受体抑制剂阿帕鲁胺进行膀胱癌化学预防
- 批准号:
10677989 - 财政年份:2022
- 资助金额:
-- - 项目类别: